NEONC TECHNOLOGIES HOLDINGS, INC. 8-K

What Happened
NEONC Technologies Holdings, Inc. announced on June 16, 2026 (via a press release furnished on Form 8‑K) that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212. NEO212 is an orally administered perillyl alcohol‑temozolomide carbamate conjugate being developed for patients with aggressive brain tumors. The company filed the Regulation FD disclosure on Form 8‑K on June 18, 2026.

Key Details

• IND status granted by the Department of Health – Abu Dhabi (DOH) for NEO212.
• NEO212 described as an oral perillyl alcohol‑temozolomide carbamate conjugate for aggressive brain tumors.
• Press release announcing the IND was dated June 16, 2026 and is furnished as Exhibit 99.1 to the Form 8‑K.
• Disclosure reported under Item 7.01 (Regulation FD Disclosure) of the Form 8‑K filed June 18, 2026.

Why It Matters
An IND grant is a regulatory milestone that allows a company to proceed with investigational clinical use of a drug in the granting jurisdiction. For investors, this represents progress in NEONC’s clinical development pathway for NEO212 and may affect the timing of trials and potential value of the asset. The filing itself is a factual disclosure of the DOH decision; further regulatory steps, trial starts, or financial impacts would be reported separately as they occur.